A matricellular protein called CCN5 has been found to reverse established cardiac fibrosis - the abnormal thickening of the heart valves, which progresses to heart failure.
Cardiac fibrosis occurs when healthy cardiac cells are replaced with fibrous connective tissue, causing scarring and a stiffer and less compliant cardiac muscle. It is found to be an independent predictor for the progression of heart failure, which accounts for approximately 450,000 deaths per year in the United States. While there currently are no effective cardiac fibrosis therapies available, it is considered a valid target for treatment.
‘Cardiac fibrosis induced in experimental animal models were treated with CCN5.The key protein was found to reverse the condition. ’
AdvertisementThe study was led by Roger J. Hajjar, MD, Professor of Medicine and Director of the Cardiovascular Research Center at the Icahn School of Medicine at Mount Sinai, and Woo Jin Park, PhD, Professor of Life Sciences at the Gwangju Institute of Science and Technology (GIST), South Korea.
"Our research is the first to demonstrate the ability to reverse cardiac fibrosis in heart failure models by targeting a specific gene," said Dr. Hajjar. "These findings demonstrate that CCN5 may provide a novel platform for the development of targeted anti-cardiac fibrosis therapies, which could benefit many patients with previously untreatable heart failure. At our Cardiovascular Research Center, we are dedicated to making significant strides in developing potential bench-to-bedside treatments for heart failure and other cardiovascular diseases."
Here, Dr. Hajjar and his team, having already established that CCN5 is significantly lower in the myocardium of patients with severe heart failure, examined whether CCN5 can reverse cardiac fibrosis in experimental models. They induced extensive cardiac fibrosis in experimental animal models of heart failure, and then proceeded to transfer CCN5 to the hearts. Eight weeks later, the team examined the cellular and molecular effects.
The results revealed that CCN5 reversed cardiac fibrosis in the models. Researchers used trichrome staining and analysis of myofibroblast contents before and after CCN5 gene transfer to clearly show the reversal. Collectively, these data demonstrate that CCN5 could potentially be used for the development of new anti-cardiac fibrosis therapies.
"Since CCN5 is a secreted protein, we may be able to deliver the CCN5 protein itself rather than the CCN5 gene in the form of recombinant virus or stem cells that are engineered to express CCN5. The efficacy of these alternative approaches has yet to be tested, but they certainly deserve serious consideration," said Dr. Park.
The therapeutic efficacy of CCN5 continues to be investigated in pre-clinical models of heart failure with extensive fibrosis.
This study funded by grants from the NIH and the Korean Government was published online today in the Journal of American College of Cardiology (JACC).
You May Also Like